Alimentary TractEfficacy and tolerability of racecadotril in acute diarrhea in children☆
Section snippets
Study population
A randomized, double-blind, placebo-controlled study was carried out in 13 separate centers. A total of 172 children hospitalized for severe acute diarrhea and aged 3 months to 4 years (mean, 12.8 months) of both sexes (71 girls and 101 boys) entered the study. Patients of both genders were included to reflect the actual use of racecadotril in routine clinical practice. The centers included 167 patients (97%). For each of these centers, the number of patients was at least 5 (range, 5–29
Study population
Of the 172 patients who entered the study (89 in racecadotril group and 83 in placebo group), 4 were excluded because their stool weights were not recorded (3 in racecadotril group and 1 placebo group). Stool weights could not be estimated in 2 other patients receiving racecadotril (1 from 12 to 24 hours and 1 from 24 to 36 hours) because no stools were passed during any other periods. These data were therefore recorded as missing.
The full data set consisted of 86 patients who received
Discussion
The results of this study establish the efficacy of racecadotril as an adjunct to oral rehydration therapy and early continued feeding in infants and children with acute diarrhea. Patients who received racecadotril had a statistically significant reduction in stool output compared with those who received placebo; the mean reduction in stool output with racecadotril was 50% in the per-protocol population and 40% in the full data set. The rapidity of effect on stool output was shown by the fact
References (30)
- et al.
Immunoautoradiographic localisation of enkephalinase (EC 3.4.24.11) in rat gastrointestinal tract
Neuropeptides
(1991) - et al.
Naloxone reversible antidiarrheal effect of enkephalinase inhibitors
Eur J Pharmacol
(1987) - et al.
Effect of loperamide on stool output and duration of acute infectious diarrhea in infants
Pediatr Pharmacol Ther
(1990) - et al.
Agents for diarrhoea in children
Lancet
(1991) A manual for the treatment of acute diarrhea for use by physicians and other senior health workers
(1984)The rational use of drugs in the management of acute diarrhoea in children
(1990)- et al.
Diarrheal mortality in two Bangladeshi villages with community based oral rehydration therapy
Lancet
(1979) Twin brush border metallo-endopeptidases
- et al.
Racecadotril demonstrates intestinal antisecretory activity in vivo
Aliment Pharmacol Ther
(1999) - et al.
Acetorphan prevents cholera toxin-induced water and electrolyte secretion in the human jejunum
Gastroenterology
(1997)
Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea
Gut
Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers
Aliment Pharmacol Ther
Racecadotril versus placebo in the treatment of acute diarrhoea in adults
Aliment Pharmacol Ther
Logarithmic transformations in ANOVA
Biometrics
A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease
N Engl J Med
Cited by (115)
Serum CD10 is associated with liver metastasis in colorectal cancer
2014, Journal of Surgical ResearchCitation Excerpt :We have earlier reported that CD10 knockdown inhibits liver metastasis of CRC cells using a mouse model [31]. Racecadotril, an antirelaxant drug, Thiorphan, and AHU377 used as antihypertensives are anti-CD10 drugs [32–34]. Application of these drugs to CRC treatment in large clinical trials might be needed to identify effective antimetastatic strategies in CRC.
Gastrointestinal drugs
2014, Side Effects of Drugs AnnualThe Efficacy and Safety of Enkephalinase Inhibitor Racecadotril in Treatment of Acute Diarrhea in Children: A Randomized Clinical Trial
2022, Journal of Comprehensive Pediatrics
- ☆
Address requests for reprints to: J. P. Cézard, M.D., Service de Gastroenterologie et Nutrition Pédiatriques, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019 Paris, France. e-mail: [email protected]; fax: (33) 1-40-03-57-66.